Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -38.52%234.49M | -58.84%25.6M | -58.10%48.37M | -38.13%70.82M | 0.43%89.7M | -1.33%381.43M | -42.15%62.18M | 0.03%115.46M | 54.68%114.47M | -0.40%89.32M |
Cost of revenue | -68.44%55.75M | -84.15%13.64M | -60.56%3.99M | -90.83%6.24M | 156.67%31.88M | 4.60%176.63M | -22.57%86.06M | -74.04%10.11M | 695.56%68.04M | 21.51%12.42M |
Gross profit | -12.72%178.74M | 150.08%11.96M | -57.87%44.39M | 39.07%64.58M | -24.81%57.82M | -5.94%204.8M | -552.99%-23.88M | 37.74%105.35M | -29.06%46.44M | -3.21%76.9M |
Operating expense | -25.82%509.54M | -23.05%105.63M | -26.16%129.64M | -28.22%127.21M | -25.29%147.07M | -13.80%686.93M | -38.65%137.28M | -14.47%175.57M | 0.94%177.22M | 2.40%196.86M |
Operating profit | 31.39%-330.8M | 41.87%-93.68M | -21.41%-85.25M | 52.11%-62.63M | 25.61%-89.24M | 16.75%-482.12M | 29.14%-161.16M | 45.47%-70.22M | -18.77%-130.79M | -6.35%-119.96M |
Net non-operating interest income (expenses) | -28.46%-13.78M | -311.22%-1.05M | -996.89%-7.42M | -533.25%-2.65M | 73.71%-2.66M | -23.77%-10.73M | -73.68%499K | 51.44%-676K | 93.53%-418K | -274.11%-10.13M |
Non-operating interest income | -18.76%3.78M | -8.80%1.96M | -49.00%255K | -66.62%255K | 5.64%1.31M | -73.00%4.65M | -52.32%2.15M | -79.89%500K | -90.32%764K | -47.15%1.24M |
Non-operating interest expense | 154.88%17.56M | 82.77%3.01M | 2,001.37%7.67M | 307.58%2.9M | -4.54%3.98M | -55.96%6.89M | -10.39%1.65M | -88.35%365K | -87.32%712K | -17.67%4.16M |
Total other finance cost | ---- | ---- | ---- | ---- | ---- | -17.20%8.49M | --0 | 8.86%811K | --470K | --7.21M |
Net investment income | 0.00%4K | 0 | -98.03%3K | |||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -2.28M | 0 | ||||||||
Income from associates and other participating interests | -276.46%-46.17M | -439.37%-42.83M | -484.75%-25.27M | -12.26M | -7.94M | -4.32M | ||||
Special income (charges) | 65.28%-103.56M | 41.25%-86.64M | 59.13M | 34.12%-99.35M | 23.3M | 51.34%-298.28M | -94.14%-147.48M | 0 | -150.8M | 0 |
Less:Other special charges | -171.20%-50.14M | -172.12%-50.21M | --3.37M | --0 | ---3.3M | -86.74%70.43M | 1,278.69%69.63M | --0 | ---- | ---- |
Less:Write off | -32.54%153.7M | 75.79%136.85M | ---62.5M | -33.77%99.35M | ---20M | 178.31%227.85M | -4.91%77.85M | --0 | --150M | --0 |
Other non-operating income (expenses) | 100.90%175K | 371.41%1.87M | -97.06%186K | -71.40%2.23M | 87.51%-4.11M | 27.17%-19.46M | -107.43%-689K | 256.88%6.33M | 553.59%7.78M | -8.70%-32.88M |
Income before tax | 39.67%-496.41M | 29.09%-224.61M | 14.92%-58.61M | 48.77%-140.48M | 55.38%-72.71M | 33.24%-822.85M | -6.54%-316.77M | 89.72%-68.89M | -129.58%-274.22M | -11.81%-162.98M |
Income tax | -92.33%6.82M | -3.37%2.21M | -99.50%26K | -99.45%433K | 63.99%4.15M | 424.82%88.91M | -67.88%2.29M | 1,821.52%5.2M | 2,613.97%78.9M | -64.96%2.53M |
Net income | 44.81%-503.22M | 28.91%-226.82M | 20.86%-58.63M | 60.10%-140.91M | 53.56%-76.86M | 27.03%-911.76M | -4.80%-319.05M | 88.94%-74.09M | -188.61%-353.12M | -8.19%-165.51M |
Net income continuous operations | 44.81%-503.22M | 28.91%-226.82M | 20.86%-58.63M | 60.10%-140.91M | 53.56%-76.86M | 27.03%-911.76M | -4.80%-319.05M | 88.94%-74.09M | -188.61%-353.12M | -8.19%-165.51M |
Noncontrolling interests | -86.05%-14.03M | 1.50%-2.96M | -183.64%-5.69M | -37.06%-3.47M | -1.91M | -135.59%-7.54M | 6.25%-3M | -2.01M | -2.53M | 0 |
Net income attributable to the company | 45.90%-489.2M | 29.17%-223.87M | 26.55%-52.95M | 60.80%-137.44M | 54.71%-74.95M | 27.45%-904.22M | -4.92%-316.05M | 89.24%-72.08M | -186.54%-350.59M | -8.19%-165.51M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 45.90%-489.2M | 29.17%-223.87M | 26.55%-52.95M | 60.80%-137.44M | 54.71%-74.95M | 27.45%-904.22M | -4.92%-316.05M | 89.24%-72.08M | -186.54%-350.59M | -8.19%-165.51M |
Gross dividend payment | ||||||||||
Basic earnings per share | 55.37%-3.49 | 40.52%-1.6 | 32.73%-0.37 | 68.06%-0.99 | 64.19%-0.53 | 38.57%-7.82 | -0.37%-2.69 | 92.12%-0.55 | -152.03%-3.1 | 19.57%-1.48 |
Diluted earnings per share | 55.37%-3.49 | 40.52%-1.6 | 37.28%-0.374 | 68.06%-0.99 | 64.19%-0.53 | 38.57%-7.82 | 1.73%-2.69 | 91.46%-0.5963 | -152.03%-3.1 | 19.57%-1.48 |
Dividend per share | ||||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |